Zilebesiran sodium
Zilebesiran (AD-85481; ALN-AGT) sodium is a long-acting liver-targeted small interfering RNA (siRNA) antihypertensive agent. Zilebesiran sodium binds to the hepatic asialoglycoprotein receptor (ASGPR), activates the RNA-induced silencing complex to degrade hepatic angiotensinogen mRNA, thereby inhibiting the gene expression and synthesis of angiotensinogen. Zilebesiran sodium dose-dependently reduces serum angiotensinogen levels and 24-hour ambulatory blood pressure, with its effect persisting throughout the circadian cycle. Zilebesiran sodium is applicable to research related to hypertension.
연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.
- CAS No.: 2380166-34-5
- 화학식: C532H678F7N177Na43O321P43S6
- 분자량:16389 (free acid)
-
보관:
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Chemical Information
-
CAS No. 2380166-34-5
-
분자량 16389 (free acid)
-
화학식 C532H678F7N177Na43O321P43S6
-
SMILES
[Zilebesiran (sodium)]
-
Synonyms
AD-85481 sodium; ALN-AGT sodium
-
선적
Room temperature in continental US; may vary elsewhere.
-
보관
Please store the product under the recommended conditions in the Certificate of Analysis.
순도&문서
References
[1]. Desai AS, Webb DJ, Taubel J, et al. Zilebesiran, an RNA Interference Therapeutic Agent for Hypertension. N Engl J Med. 2023;389(3):228-238. doi:10.1056/NEJMoa2208391 [Content Brief]
[2]. Dudzicz-Gojowy S, et al. Zilebesiran-Small Interfering RNAs as Prospective New Drug in the Treatment of Hypertension. J Clin Med. 2025;14(20):7365. Published 2025 Oct 17. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)